You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: May 5, 2024

Claims for Patent: 4,251,510

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 4,251,510

Title:	Intravenously injectable solution of plasma protein fraction free from bradykinin, kininogen and prekallikrein activators and processes for its production
Abstract:	Plasma Protein Fraction substantially free of bradykinin, kininogen and prekallikrein activators is obtained by treating Cohn Supernatant II plus III at about neutrality with a siliceous substance for a period of time sufficient to bring about essentially complete conversion of intrinsic kininogen into bradykinin. Subsequently, after being separated from Cohn Fraction IV-1, the Plasma Protein Fraction is reconstituted and held for a period of time sufficient to allow substantially complete destruction of bradykinin by kininase. Methods are disclosed for the destruction of prekallikrein activators which may be present in Plasma Protein Fraction.
Inventor(s):	Tankersley; Donald L. (Rockville, MD)
Assignee:	Cutter Laboratories, Inc. (Berkeley, CA)
Application Number:	06/066,757
Patent Claims:	1. A sterile aqueous solution of heat-stable Plasma Protein Fraction (Human) suitable for injection, wherein about 5 grams of Plasma Protein Fraction (Human) per 100 milliliters of sterile aqueous solution contains no greater than about 16 milli-units per milliliter Factor XIIa and fragments thereof capable of activating prekallikrein, no greater than about 10 nanograms bradykinin equivalents per milliliter of kininogen, and less than about 10 nanograms per milliliter of bradykinin, said Plasma Protein Fraction (Human) being a mixture of constituent plasma protein isolated from human plasma by a modified Cohn fractionation process and containing at least 83% albumin and no more than 17% alpha and beta globulins having molecular weights similar to that of albumin and no more than 1% gamma globulin. 2. The solution of claim 1 wherein the protein concentration is about 5 percent. 3. The solution of claim 1 which includes a stabilizer selected from the group consisting of sodium acetyltryptophan and sodium caprylate.

Details for Patent 4,251,510

Glossary

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Grifols Therapeutics Llc	PLASMANATE	plasma protein fraction (human)	Injection	101140	10/02/1958	⤷ Try a Trial	1998-02-17
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.